Citron’s Andrew Left Tight-Lipped On Valeant Position

0
Citron’s Andrew Left Tight-Lipped On Valeant Position


Citron Research executive editor Andrew Left, explains his trading is not relevant to the Valeant story.

Citron’s Andrew Left tight-lipped on Valeant position

Citron’s Left: I put out info that was true

Citron Research executive editor Andrew Left, addresses Valeant Pharmaceuticals’ critical response to his report on the company.

GrizzlyRock: Long Thesis For This European Travel Company [Q1 Letter]

TravelGrizzlyRock Value Partners was up 16.6% for the first quarter, compared to the S&P 500's 5.77% gain and the Russell 2000's 12.44% return. GrizzlyRock's long return was 22.3% gross, while its short return was -2.9% gross. Compared to the Russell 2000, the fund's long portfolio delivered alpha of 10.8%, while its short portfolio delivered alpha Read More


Citron: Not contacted by SEC

Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story and the Enron analogy.

Citron: Valeant should be the focus, not us

Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story in an effort to walk away from the story.

Citron: Easier to pass Citron story to mainstream media

Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story.

No posts to display